Claude

The Numbers

Centene trades at $37.28, roughly 12.4x its 2026 guided adjusted EPS of >$3.00 and 0.10x trailing revenue – among the cheapest multiples in managed care. The stock is down 40% over the past year, punished by a $6.7 billion goodwill impairment, a 360 bps HBR blow-up, and a collapse in Marketplace risk-adjustment revenue. The single metric most likely to rerate this stock is the health benefits ratio: if Centene can demonstrate HBR improvement toward 89% through repriced Marketplace books and Medicaid rate catch-ups in 2026, the path to $3+ adjusted EPS becomes credible and the multiple could expand meaningfully.

Valuation Snapshot

The stock sits 42% below its 52-week high and 16% below the consensus analyst target of $43.18. At 0.87x book value, the market is effectively saying the goodwill write-down was justified and future earnings power is impaired. With 2026 adjusted EPS guided above $3.00 – a 44% year-over-year increase from FY2025's $2.08 – the forward multiple appears undemanding if management delivers.

Revenue and Earnings Power

Revenue has grown at a 10% CAGR over the past three years, accelerating to 19% in FY2025 driven by PDP premium yield and Marketplace membership growth. The 2026 revenue guidance of $186.5-190.5B implies a headline decline, but this reflects the transition away from lower-margin pass-through premium tax revenue and divestitures, not organic shrinkage. The real story is the earnings collapse: adjusted EPS fell 71% in FY2025 as the HBR spiked 360 bps, wiping out operating leverage. The 2026 guide of >$3.00 represents recovery, not growth, from a deeply depressed base.

Segment Revenue Mix

The Commercial segment (primarily Marketplace) was the biggest margin casualty, losing $2.6B in gross margin year-over-year due to lower risk-adjustment revenue and higher medical costs. Medicaid margins also deteriorated by $556M from behavioral health, home health, and high-cost drug pressures. Medicare was the lone bright spot, gaining $388M on PDP growth from IRA-driven structural changes.

The Critical Chart: Health Benefits Ratio

SG&A efficiency improved from 9.3% to 7.4% over three years – meaningful operating leverage. But the HBR expansion more than offset it. Every 100 bps on HBR is worth roughly $1.7B in pre-tax income on a $171B premium base.

Cash Generation

FY2025 cash generation recovered powerfully to $5.1B in operating cash flow ($4.3B FCF) after the anomalous $154M in FY2024 caused by PBM transition timing. At a 23.6% FCF yield on the current market cap, Centene is generating cash at a rate that would allow it to buy back 23% of its equity annually – although management significantly slowed buybacks to $400M in 2025 versus $3.0B in 2024 given the earnings uncertainty.

Balance Sheet and Leverage

The debt-to-capital ratio jumped to 46.5% in FY2025, but this was driven by the $6.7B goodwill impairment shrinking equity, not by new borrowing. Actual debt decreased. Senior notes total $15.5B with maturities from 2027-2031. The revolving credit facility ($4.0B, undrawn) matures in March 2030. Regulatory subsidiaries hold $19.7B in statutory capital against $11.3B required – a comfortable 1.7x buffer. In February 2026, the Board authorized an additional $1.0B debt repurchase program, signaling confidence in deleveraging.

Membership Dynamics

Medicaid membership has declined 13.5% since Dec-2023 as post-COVID redeterminations removed lower-acuity members, leaving a sicker (higher-cost) population. Marketplace grew 26% YoY to 5.5M members. PDP surged 76% over two years to 8.1M on favorable IRA-driven positioning. Medicare Advantage declined 22% over two years as Centene pruned unprofitable plans, targeting MA breakeven by 2027.

Peer Comparison

Centene trades at the lowest EV/Revenue in the peer group (0.10x vs peer median of 0.18x) and a middle-of-the-pack forward P/E of 12.4x. The discount reflects: (1) the HBR blow-up and earnings uncertainty, (2) the goodwill impairment overhang, and (3) disproportionate Medicaid exposure (64% of membership) amid OBBBA regulatory risk. UnitedHealth commands a clear premium at 18x given its diversified Optum business and consistent execution.

Capital Allocation

The shift from aggressive buybacks ($3.1B in 2024, $1.6B in 2023) to conservation ($475M in 2025) tells the story: management is preserving capital during the earnings trough. The company repaid $1.1B of debt net in 2025 and still has $1.8B remaining on its buyback authorization. A February 2026 Board authorization added $1.0B to the debt repurchase program, signaling a near-term priority on deleveraging over share buybacks.

Share count has declined 15% since 2021, from 582M to 493M. However, the pace has slowed markedly – only 6.7M shares repurchased in 2025 versus 42M in 2024. At current prices, the remaining $1.8B authorization could retire roughly 48M shares (10% of float), providing meaningful per-share earnings accretion once the buyback resumes.

Annual Stock Price

The stock has lost 55% of its value since 2021, with the steepest declines occurring after the Q2 2025 earnings miss (the first in four years) and the $6.7B goodwill write-down in Q3 2025. At $37.28, CNC trades below its book value for the first time in its modern history as a public company.

What the Numbers Confirm, Contradict, and What to Watch

The numbers confirm that Centene's earnings power has been severely impaired by the HBR spike, particularly in Marketplace where risk-adjustment revenue swung negative and medical costs rose simultaneously. The $6.7B goodwill write-down was an accounting acknowledgment of what the market had already priced.

The numbers contradict the idea that the business is broken: FY2025 operating cash flow of $5.1B was the second-highest in company history, Medicaid contract wins remain strong across multiple states, and the SG&A ratio reached a record low of 7.4%. The enterprise generates real cash even when GAAP earnings are negative.

Watch Q1 2026 HBR closely on the April 28 earnings call. Management repriced 95% of Marketplace states for 2026 and is targeting margin improvement across all three core segments. If HBR comes in below 90%, the stock likely rerates higher. If it doesn't, the $3+ adjusted EPS guide is at risk.